Medicine and Dentistry
Ovarian Cancer
100%
Vasculotropin Inhibitor
100%
Biliary Tract Cancer
100%
Blood Vessel Reactivity
100%
Biological Marker
50%
Cediranib
50%
Neoplasm
33%
Colorectal Cancer
33%
Placebo
33%
Deterioration
16%
Disease Exacerbation
16%
Gemcitabine
16%
Hazard Ratio
16%
Overall Survival
16%
Student T Test
16%
Progression Free Survival
16%
Progressive Disease
16%
Cisplatin
16%
Bevacizumab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
100%
Ovary Cancer
100%
Vasculotropin Inhibitor
100%
Biliary Tract Cancer
100%
Biological Marker
50%
Cediranib
50%
Neoplasm
33%
Placebo
33%
Cisplatin
16%
Disease
16%
Disease Exacerbation
16%
Gemcitabine
16%
Deterioration
16%
Bevacizumab
16%
Overall Survival
16%
Progression Free Survival
16%
Immunology and Microbiology
Blood Plasma
100%
Blood Vessel Reactivity
100%
Hepatobiliary System
100%
Vasculotropin Inhibitor
100%
Cediranib
33%
Bevacizumab
11%
Overall Survival
11%
Progression Free Survival
11%
Biochemistry, Genetics and Molecular Biology
Vascular Endothelial Growth Factor
100%
Blood Vessel Reactivity
100%
Cediranib
50%
Gemcitabine
16%
Bevacizumab
16%
Overall Survival
16%
Progression Free Survival
16%
Cisplatin
16%